Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.52 |
| ▸ | ACP1 | P24666 | 6/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168705 | 0.84 | AKR1C3 (0.42) | PDE4BSQORSIRT2 | |
| SCHEMBL29442375 | 0.83 | SQOR (0.62) | SQORLIMK1 | |
| SCHEMBL10168707 | 0.82 | S1PR1 (0.45) | PDE4BSQORSIRT2SIRT1 | |
| SCHEMBL25148654 | 0.80 | SQOR (0.50) | SQORLIMK1 | |
| SCHEMBL25149086 | 0.80 | SMN1; SMN2 (0.50) | SQORCDK1LIMK1 | |
| SCHEMBL5765632 | 0.77 | MAPK8 (0.47) | — | |
| SCHEMBL25149336 | 0.74 | SQOR (0.49) | SQORLIMK1 | |
| SCHEMBL25149434 | 0.73 | SQOR (0.51) | SQORLIMK1 | |
| SCHEMBL4060916 | 0.73 | ACP1 (0.50) | PDE4BACP1ABCB1ABCG2SQOR | |
| SCHEMBL25148764 | 0.73 | SMN1; SMN2 (0.54) | SQOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | PDE4B 620/4885ACP1 483/4885ABCB1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.